Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis

Overview

Journal J Pediatric Infect Dis Soc

Publisher Oxford University Press

Specialties Infectious Diseases
Pediatrics

Date 2020 May 26

PMID 32448902

Citations 3

Authors

Paul Krogstad

Pearl Samson

Edward P Acosta

Jack Moye

Ellen Townley

Sarah Bradford

Emily Brown

Kayla Denson

Bobbie Graham

Laura Hovind

Thucuma Sise

Hedy Teppler

Sisinyana Ruth Mathiba

Lee Fairlie

Jana L Winckler

Gretchen Slade

Tammy Meyers

Affiliations

Soon will be listed here.

Abstract

Clinical Trials Registration: NCT01751568.

Citing Articles

Pharmaceutical Equivalence of Film-Coated and Chewable Tablets: A Comparative Dissolution Study Using Pulverized Chewable Tablets.

Park S, Choi S Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598435 PMC: 11597698. DOI: 10.3390/ph17111525.

Review on fluorinated nucleoside/non-nucleoside FDA-approved antiviral drugs.

Ismail M, Ayoup M RSC Adv. 2022; 12(48):31032-31045.

PMID: 36348998 PMC: 9620415. DOI: 10.1039/d2ra05370e.

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.

Jacobs T, Svensson E, Musiime V, Rojo P, Dooley K, McIlleron H J Antimicrob Chemother. 2020; 75(12):3433-3457.

PMID: 32785712 PMC: 7662174. DOI: 10.1093/jac/dkaa328.

References

Rabie H, Denti P, Lee J, Masango M, Coovadia A, Pillay S . Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. Lancet HIV. 2018; . DOI: 10.1016/S2352-3018(18)30293-5. View

Meyers T, Samson P, Acosta E, Moye J, Townley E, Bradford S . Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. AIDS. 2019; 33(14):2197-2203. PMC: 7232968. DOI: 10.1097/QAD.0000000000002369. View

Wenning L, Hanley W, Brainard D, Petry A, Ghosh K, Jin B . Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009; 53(7):2852-6. PMC: 2704654. DOI: 10.1128/AAC.01468-08. View

Bhatt N, Baudin E, Meggi B, da Silva C, Barrail-Tran A, Furlan V . Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. J Antimicrob Chemother. 2014; 70(1):225-32. PMC: 4267502. DOI: 10.1093/jac/dku348. View

Ren Y, Nuttall J, Eley B, Meyers T, Smith P, Maartens G . Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2009; 50(5):439-43. DOI: 10.1097/QAI.0b013e31819c33a3. View